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IntroductIon
Narcolepsy type 1 (hereafter called narcolepsy) is a rare, 
chronic, and disabling neurological disease characterized by 
excessive daytime sleepiness, sudden loss of muscle tone trig-
gered by emotions, and fragmented nocturnal sleep (Dauvil-
liers et al., 2007; Scammell, 2015). Narcolepsy is caused by 
defective neurotransmission via orexin (also named hypo-
cretin) neuropeptides, resulting from a selective and irrevers-
ible loss of orexinergic neurons in the lateral hypothalamus. 
The disease etiology is largely unclear but narcolepsy has a 
strong genetic association with the human leukocyte anti-
gen (HLA)-DQB1*06:02 allele, which is present in >98% 
of patients versus 18% of control Europeans (Mignot et al., 
1997; Tafti et al., 2014). Additionally, narcolepsy is associ-
ated with other genes relevant to immune responses, most 
notably HLA class I alleles and T cell receptor α (TCRA) 
polymorphisms (Han et al., 2013; Ollila et al., 2015; Tafti et 
al., 2016). These findings provide the main reasoning behind 
why narcolepsy is generally considered an immune-mediated 
disorder involving autoaggressive lymphocytes. In line with 
this hypothesis, autoantibodies of unknown pathogenic rel-
evance have been identified in some individuals with nar-
colepsy (Cvetkovic-Lopes et al., 2010; Bergman et al., 2014; 
Ahmed et al., 2015; Saariaho et al., 2015). Further supporting 
an autoimmune etiology is the fact that vaccination against 
the 2009 pandemic H1N1 influenza virus with the Euro-
pean preparation Pandemrix was associated with induction of 
narcolepsy in individuals harboring the HLA-DQB1*06:02 
allele (Nguyen et al., 2016). Although these points provide 
indirect evidence for an immune-mediated pathogenesis 
in narcolepsy, studies identifying the involved immune cell 
types and investigating their function and phenotype remain 
scarce (Liblau et al., 2015).
The recent advent of high-dimensional single-cell anal-
ysis techniques such as mass cytometry (also called cytometry 
by time-of-flight [CyTOF]) now permits in-depth exam-
ination of multiple immune cell subtypes simultaneously 
and, together with algorithm-guided analysis approaches, 
provides an ideal platform for such explorative studies 
(Bendall et al., 2012).
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Here, we analyzed PBMCs of a large cohort of narco-
lepsy patients and healthy control individuals harboring the 
HLA-DQB1*06:02 allele via mass cytometry. Using new 
and powerful automated algorithms enabled an explorative, 
hypothesis-generating interrogation of the phenotypic and 
functional immune signature of narcolepsy. For this, we es-
tablished a 45-parameter panel, including 22 cell surface and 
13 intracellular heavy metal–conjugated antibodies, which 
were chosen to (i) identify all major immune populations in 
peripheral blood of humans, (ii) determine their activation 
status, and (iii) analyze their maturation, chemokine receptor 
(CCR), and most importantly, cytokine expression patterns. 
Using this approach revealed a proinflammatory signature of 
T cells in narcolepsy patients, dominated by elevated levels of 
B cell–supporting cytokines.
reSuLtS
Single-cell mass cytometry for the analysis of immune 
populations in narcolepsy
We collected PBMCs from narcolepsy patients (n = 39), 
tightly age-, sex-, and HLA-DQB1–matched healthy donors 
(HD; n = 25), as well as patients with other hypersomnias 
(n = 11; Table 1 and more detailed in Table S1). This collec-
tion included narcolepsy patients with a wide range of disease 
durations (8–552 mo), as well as patients in which the onset of 
narcolepsy occurred after Pandemrix H1N1 influenza virus 
vaccination (n = 11) or independently of it. Additionally, the 
inclusion of patients with other hypersomnias allowed us to 
control for and directly compare the influence of nonauto-
immune sleep disorders.
Given the uncertainty about potential autoantigens 
in narcolepsy, we brieftly restimulated the PBMC samples 
in an antigen-independent manner (PMA/ionomycin) and 
performed live-cell barcoding before the combined sample 
was stained with heavy metal–conjugated antibodies (Table 
S2) and acquired on a CyTOF2 mass cytometer (Fig. 1 A). 
After data preprocessing, the FlowSOM algorithm (Van Gas-
sen et al., 2015) was used to identify the major immune cell 
populations in a data-driven and automated manner. Flow-
SOM assigned cells to clusters corresponding to the major 
immune populations (CD4+ and CD8+ T cells, γδT cells, B 
cells, NK cells, and monocytes, Fig. 1 B). Visualization of the 
high-dimensional data using the t-stochastic neighbor em-
bedding (t-SNE) algorithm (Van Der Maaten and Hinton, 
2008; Amir et al., 2013; Mair et al., 2016) corresponded well 
to the automatically defined populations, thus further veri-
fying the FlowSOM clustering (Fig. 1 C). The defined pop-
ulations from different samples were homogeneous in their 
expression levels of all analyzed markers and clearly distinct 
from other clusters (Fig. 1 D).
First, we investigated whether the relative frequencies 
of the major immune cell populations are modulated in nar-
colepsy patients versus HD and hypersomnia patients (Fig. 1, 
E and F; and together with all measured frequencies in Table 
S3). We found the composition of the PBMCs to be largely 
comparable between patients and controls, with a slight re-
duction in the frequency of monocytes (1.0 ± 0.6% HD ver-
sus 0.2 ± 0.1% Narco, median ± SEM), as well as NK cells 
and γδT cells. To further define functional subsets of the pre-
viously identified immune lineages, we again used FlowSOM 
to automatically subdivide total CD4+ and CD8+ T cells 
into CD45RA+CCR7+ naive, CD45RA+CCR7− effector, 
CD45RA−CCR7− effector memory and CD45RA−CCR7+ 
central memory cells (Fig.  1  G). Narcolepsy patients were 
found to have higher proportions of naive CD4+ (37.6 ± 
4.1% Narco vs. 22.7 ± 3.9% HD) and CD8+ T cells (46.7 ± 
2.4% Narco vs. 23.7 ± 7.0% HD) co-occurring with fewer 
respective effector memory T cells.
Activation and increased production of tnF and B cell–
supporting cytokines by th cells
Having automatically defined different leukocyte populations, 
we next assessed whether their activation status and especially 
cytokine profiles are altered in narcolepsy. Starting with CD4+ 
Th cells, we found that CD69 expression was elevated on 
previously defined CD45RA+CCR7+ Th cells in narcolepsy 
patients (21.8 ± 1.3%) versus HD (11.3 ± 2.8%, Fig. 2 A). 
With the exception of two donors, this increase was not ob-
served in patients with other sleep disorders (16.4 ± 2.7%). 
Interestingly, a higher frequency of CD69 expression was fur-
ther confirmed in a monozygotic twin pair discordant for 
the disease (N09 and HD01), where the narcoleptic twin also 
expressed increased levels of CD69 on CD45RA+CCR7+ Th 
cells compared with the healthy sibling (Fig. 2 B).
Given the high-dimensional nature of mass cytometry, 
we were able to simultaneously analyze the production of 
up to 12 cytokines on antigen-experienced CD4+ T cells. 
Manually defining cytokine-positive cells, we found the fre-
Table 1. Summary characteristics of patients and control subjects in this study
Patients N Age Sex (male/
female)
HLA-DQB1*06:02 
positive
Prior Pandemrix 
immunization
Disease 
duration 
CSF orexin levels 
<110 pg/ml (N/N 
tested)
CSF orexin levels 
>200 pg/ml (N/N 
tested)
yr mo
Healthy donors 25 47 (13–64) 16/9 25
Narcolepsy type 1 39 42 (13–64) 23/16 39 11 59 (8–552) 32/32
Other hypersomnias 11 25 (6–54) 3/8 10/10
For age and disease duration, numbers indicate the median with the range in parentheses.  
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quency of TNF and IL-2–producing cells to be increased in 
antigen-experienced Th cells from narcolepsy patients (63.9 
± 4.2% TNF and 54.6 ± 2.7% IL-2) versus HD (47.5 ± 
2.3% TNF and 46.2 ± 5.9% IL-2). Importantly, patients with 
other hypersomnias resembled HD (53.1 ± 8.7% TNF and 
39.7 ± 12.0% IL-2; Fig.  2  C). Additionally, the frequency 
of several Th2-associated cytokines, such as IL-4 and IL-13, 
was increased in narcolepsy patients (3.5 ± 0.5% IL-4 and 
3.5 ± 0.2% IL-13) versus HD (2.6 ± 0.3% IL-4 and 2.5 ± 
0.2% IL-13). To a lesser extent, IL-3 did also show an in-
creased frequency in narcolepsy patients. Again, patients 
with other hypersomnia did not show these augmented 
frequencies. The frequency of IL-6–producing Th cells was 
reduced in narcolepsy patients compared with controls, 
whereas IL-21–producing cells displayed a trend toward a 
higher frequency in narcolepsy patients (5.0 ± 0.7% Narco 
vs. 3.5 ± 0.4% HD; P = 0.049).
The frequencies of IFN-γ+ and IL-17A+ T cells, which 
are heavily implicated in other autoimmune diseases, includ-
ing multiple sclerosis (Dendrou et al., 2015) and psoriasis 
(Becher and Pantelyushin, 2012; Perera et al., 2012), were not 
overtly altered in narcolepsy patients, as was the production 
of the immunosuppressive IL-10 by Th cells (Fig. 2, C–G). A 
more detailed analysis of individual subpopulations provided 
similar results for effector, effector memory, and central mem-
ory Th cells, demonstrating that the augmented cytokine 
Figure 1. High-dimensional mass cytometry for the analysis of immune populations in narcolepsy patients. (A) PBMCs of narcolepsy patients 
(Narco, n = 39), HD (n = 25) and patients with other hypersomnias (n = 11) were stained with heavy metal–labeled antibodies and acquired on a CyTOF2 
mass cytometer. (B) Data from preprocessed, single, live cells was exported and used as input for the FlowSOM clustering algorithm. Only the 10 indicated 
surface markers were used in this initial clustering step. FlowSOM nodes were metaclustered (k = 8) and manually annotated based on the expression level 
of the lineage-associated markers. RO+, CD45RO+; RA+, CD45RA+. (C) The combined dataset was down-sampled to 20,000 cells and subjected to dimen-
sionality reduction using the t-SNE algorithm. Again, only the 10 surface markers indicated in B were used as input dimensions. The manually annotated 
populations from C are overlaid as a color-dimension. (D) Instead of cells, clusters from the combined dataset and all measured parameters were used as 
an input for the t-SNE visualization. (E) Statistical comparison of the frequencies of immune populations and (F) sample-specific composition in narcolepsy 
patients and controls. Indicated p-values are comparing narcolepsy patients with HD. (G) T cells were automatically subdivided into naive, effector, effector 
memory, and central memory cells based on the expression of CD45RA and CCR7 using FlowSOM (k = 4, left). Composition of CD4+ and CD8+ T cell subsets 
in narcolepsy patients versus HD (right). Boxplots represent the interquartile range (IQR) with a black horizontal line indicating the median. Whiskers extend 
to the farthest data point within a maximum of 1.5× IQR. Values outside this range are plotted as points. All p-values were calculated using a nonparamet-
ric Mann-Whitney-Wilcoxon test. Controlling for multiple comparisons was performed with the Benjamini-Hochberg approach. **, significant with false 
discovery rate (FDR) < 5%; ***, significant with FDR < 1%.
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production in narcolepsy patients is not driven by a specific 
subset (unpublished data).
To identify Th cell subsets based on the coexpression 
of the aforementioned cytokines in a more unbiased and 
data-driven approach, we again made use of the FlowSOM 
clustering algorithm. FlowSOM identified several subsets of 
Th1 and Th2 cells, as well as Th cells resembling Th17, Th22, 
and regulatory T (T reg) cell subsets (Fig.  2, E–H). Using 
this data-driven subset identification, we found the fraction 
of cytokine-negative cells to be markedly reduced in nar-
colepsy patients (37.8 ± 2.7%), compared to patients with 
other hypersomnias (54.9 ± 14.3%) or HD (51.5 ± 6.0%). In-
Figure 2. Activation and increased th cell cytokine production in narcolepsy patients. FlowSOM-defined CD4+ Th cells of narcolepsy patients 
(Narco, n = 39), HD (n = 25), and patients with other hypersomnias (n = 11) were examined for CD69 expression and cytokine production. (A) Heat map 
depiction of the individual frequency of CD69+ cells in CD45RA+CCR7+ Th cells was sorted from highest to lowest frequency for all narcolepsy patients and 
controls within the cohort. Each square represents one individual. (B) CD69 expression by CD45RA+CCR7+ Th cells in a monozygotic twin pair discordant for 
narcolepsy. (C) Manually determined frequencies of cytokine+ antigen-experienced (effector, effector memory, and central memory) Th cells. (D) Production 
of TNF, IL-2, and IL-17A by Th cells as in C. (E) FlowSOM (k = 17) was used to cluster Th cells based on their cytokine-production profiles. The major Th cell 
subsets were manually annotated using these cytokine production profiles in combination with their CCR expression. (F) Group-specific composition and 
(G) statistical comparison of the frequencies of Th cell subsets in narcolepsy patients and controls. (H) Frequencies of the indicated regulatory immune cell 
populations were defined by manual gating. T reg cells were defined as CD25+CD127−IL-2− Th cells. Boxplots represent the IQR with a black horizontal line 
indicating the median. Whiskers extend to the farthest data point within a maximum of 1.5× IQR. Values outside this range are plotted as points. All p-values 
were calculated using a nonparametric Mann-Whitney-Wilcoxon test and are comparing narcolepsy patients with HD. Controlling for multiple comparisons 
was performed with the Benjamini-Hochberg approach. *, significant with FDR < 10%; **, significant with FDR < 5%.
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stead, narcolepsy patients had a strongly increased frequency 
of TNF+IL-2+, but IFN-γ−, Th cells (32.8 ± 1.8% Narco vs. 
21.6 ± 4.0% HD). Confirming the results obtained using 
manual gating, this automated clustering also identified in-
creased frequencies of Th2 cells in narcolepsy patients (6.1 ± 
0.9%) vs. HD (2.7 ± 0.5%).
Augmented cytokine production might stem from 
changes in the frequency of regulatory immune subsets. 
However, we did not find any overt modulation of the fre-
quency of T reg cells, IL-10–producing B cells, or CD56high 
NK cells in narcolepsy patients versus controls (Fig. 2 H).
expansion of B cell–supporting cd8+ t cell populations
Besides CD4+ Th cells, CD8+ T cells are also thought to 
play a major role in CNS inflammation and autoimmunity 
(Waisman et al., 2015; Yshii et al., 2015), and in an exper-
imental model of narcolepsy (Bernard-Valnet et al., 2016). 
Based on the activation and overt modulation of cytokine 
production by CD4+ T cells, we analyzed whether in nar-
colepsy patients, CD8+ T cell subsets are activated and show 
altered cytokine production profiles. Comparing CD69 ex-
pression on CD45RA+CCR7+ CD8+ T cells in narcolepsy 
patients versus HD, we did not find significant differences in 
the activation state of this population (Fig. 3 A).
We found increased frequencies of TNF and IL-2 pro-
ducing CD8+ T cells in narcolepsy patients (57.7 ± 3.7% TNF 
and 34.0 ± 2.3% IL-2) compared with HD (45.7 ± 2.7% 
and 25.4 ± 4.1%, respectively; Fig. 3, B and C). Additionally, 
GM-cerebrospinal fluid (CSF) and type 2 cytokines (IL-3, 
IL-4, and IL-13) were also augmented in CD8+ T cells of nar-
colepsy patients. Similar to CD4+ T cells, the levels of IFN-γ– 
and IL-17A–producing cells were not differentially regulated 
in narcolepsy patients versus control groups. Production of 
IL-6 or Granzyme B by CD8+ T cells was also comparable 
between narcolepsy patients (10.8 ± 1.9% Granzyme B) and 
HD (11.8 ± 2.1% Granzyme B; Fig. 3 C). Notably, the CD8+ 
T cell cytokine profile was similar between patients with 
other hypersomnias and HD and thus very distinct from that 
of narcolepsy patients (Fig. 3, B and C).
Next, again using an algorithm-guided approach, we 
clustered antigen-experienced CD8+ T cells based on their 
cytokine production profiles and annotated these clusters into 
TC1, TC2, cytokine-negative, and other subtypes (Fig. 3 D). 
Comparing the frequencies of these CD8+ T cell subsets, we 
found a striking increase in TC2-like cells in narcolepsy pa-
tients (11.7 ± 1.7%) compared with HD (5.8 ± 1.7%) and 
to patients with other hypersomnias (5.9 ± 2.0%; Fig. 3, E 
and F). This increase seemed to be at the expense of cyto-
kine-negative cells, which were decreased in narcolepsy. 
The frequency of TC1-like cells was comparable in all three 
groups (Fig. 3, E and F).
Given the prominent production of B cell–supporting 
cytokines by CD4+ and CD8+ T cells, we examined cytokine 
expression profiles of B cells in narcolepsy patients (Fig. 3 G). 
The frequency of B cells producing IL-6 (7.4 ± 0.6% Narco 
vs. 5.7 ± 0.5% HD) and TNF (43.3 ± 2.0% Narco vs. 37.3 
± 1.9% HD) was augmented in narcolepsy patients; however, 
increased TNF production was also observed in patients with 
other hypersomnias (50.7 ± 7.0%).
technical stability of narcolepsy immune phenotyping
To confirm the narcolepsy-associated immune phenotypes, 
we performed repeated measurements of narcolepsy samples 
from the same and different blood draws (Fig. 4). Frequencies 
of immune phenotypes from independent measurements of 
separate aliquots taken from a single blood draw displayed a 
strong correlation, thus demonstrating the technical repro-
ducibility of the method (Fig. 4 A). Further, samples drawn 
from patients on different occasions also displayed virtually 
identical immune phenotypes (Fig. 4 B), resembling the cor-
relation of repeated measurements of the same samples.
narcolepsy-associated immune phenotypes in 
Pandemrix-vaccinated patients
The cohort of narcolepsy patients comprised patients with a 
broad range of disease durations (8–552 mo). Among patients 
with shorter disease duration (median, 44 mo; range, 8–72 
mo) were individuals in whom the onset of narcolepsy oc-
curred after Pandemrix immunization (n = 11; Narco Pan) 
and patients who did not receive the Pandemrix vaccine 
(n = 12). Comparing these groups of patients matched for 
disease duration and age, we found that Pandemrix-vacci-
nated and non–Pandemrix-vaccinated patients displayed no 
statistically significant difference in the aforementioned im-
mune phenotypes (Fig. 5).
narcolepsy-associated immune phenotypes are influenced 
by age and disease duration
Next, we determined whether the immune alterations ob-
served in narcolepsy patients versus controls are associated 
with any clinical characteristic (Table S1). First, using linear 
modeling, we assessed the influence of age and disease dura-
tion on immune phenotypes in narcolepsy patients and HD. 
We found a detectable influence of age to several immune fre-
quencies in narcolepsy patients and HD, accounting in part for 
the variance in these phenotypes (median R2 = 0.1; Fig. 6 A).
Interestingly, narcolepsy-associated cytokine production 
by CD4+ and CD8+ T cells tended to increase with age in pa-
tients but not in HD (Fig. 6 B). In contrast, these trends were 
reversed for CD69 expression on T cells. As expected, the age 
of the narcolepsy patients correlated with disease duration. 
Therefore, we constructed a linear model using both variables 
as predictors to assess their relative importance. Disease dura-
tion and age both contributed almost equally to the explained 
variance in the immune phenotype of the narcolepsy patients 
(mean proportion of R2 0.44 and 0.56, respectively; Fig. 6 C).
Narcolepsy, like many other chronic diseases, has several 
clinical manifestations and comorbidities which may influ-
ence immune parameters. To control for potential confound-
ing factors to the reported immunological phenotypes, we 
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next investigated the contribution of patients’ clinical and 
neurophysiological characteristics, such as subjective (using 
the Epworth sleepiness scale [ESS]) and objective measures 
of daytime sleepiness (using the multiple sleep latency test 
[MSLT] and the number of sleep-onset rapid-eye-movement 
periods [SOR EMPs]), disturbed sleep at night (using the in-
somnia severity index [ISI]), body-mass index (BMI), and 
self-reported depression (using the Beck depression inven-
tory or children’s depression inventory [BDI/CDI]), as well 
as the patient’s treatment status (Fig. 6 D). We found that only 
IL-4 production by CD8+ T cells correlated with one of these 
parameters (BMI), whereas we did not observe any substantial 
influence of all other parameters on any of the analyzed im-
munological phenotypes (Fig. 6 D).
Figure 3. expansion of B cell-supporting cd8+ t cells in narcolepsy. FlowSOM-defined CD8+ T cells of narcolepsy patients (Narco, n = 39), HD (n = 
25), and patients with other hypersomnias (n = 11) were examined for CD69 expression and cytokine production. (A) Heat map depiction of the frequency 
of CD69+ cells in CD45RA+CCR7+ CD8+ T cells was sorted from highest to lowest frequency for all narcolepsy patients and controls. Each square represents 
one individual. (B) Manually determined frequencies of cytokine+ antigen-experienced (effector, effector memory, and central memory) CD8+ T cells and 
(C) statistical comparison of the frequencies of cytokine+ cells. (D) FlowSOM (k = 17) was used to cluster antigen-experienced CD8+ T cells based on their 
cytokine-production profiles. The major CD8+ T subsets were manually annotated using these cytokine production profiles in combination with their CCR 
expression. (E) Group-specific composition and (F) statistical comparison of the frequencies of CD8+ T cell subsets in narcolepsy patients and controls. (G) 
Manually gated frequencies of cytokine+ B cells. Boxplots represent the IQR with a black horizontal line indicating the median. Whiskers extend to the 
farthest data point within a maximum of 1.5× IQR. Values outside this range are plotted as points. All p-values were calculated using a nonparametric 
Mann-Whitney-Wilcoxon test and compare narcolepsy patients with HD. Controlling for multiple comparisons was performed with the Benjamini-Hoch-
berg approach. *, significant with FDR < 10%; **, significant with FDR < 5%; ***, significant with FDR < 1%. 
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dIScuSSIon
In this study, we performed a comprehensive, explorative 
analysis of narcolepsy type 1 patients in which we studied 
numerous immunological phenotypes at the single-cell level. 
To do so, we made use of mass cytometry, which in combina-
tion with unbiased, data-driven analysis methods, has proven 
to be a valuable tool in the hypothesis-free identification of 
cellular phenotypes associated with cancer (Behbehani et al., 
2015; Levine et al., 2015) or clinical recovery after surgery 
(Gaudillière et al., 2014). Using this approach in the context 
of a more elusive, putative autoimmune disease, we found 
complex patterns of immune activation in narcolepsy pa-
tients. Central to many of these narcolepsy-associated phe-
notypes was their association with B cell–mediated immune 
responses. This is in line with previous indications of autoan-
tibodies in narcolepsy (Cvetkovic-Lopes et al., 2010; Berg-
man et al., 2014; Ahmed et al., 2015; Saariaho et al., 2015) 
and recent studies that further support an important role of B 
cells in the pathogenesis of T cell–driven CNS autoimmunity 
(Krumbholz et al., 2012; Flach et al., 2016).
Specifically, we found that CD4+ and CD8+ T cells of 
narcolepsy patients produced elevated levels of several cy-
tokines involved in B cell differentiation, including IL-4, 
IL-13, and IL-21. In addition, we found strikingly elevated 
frequencies of TNF and IL-2–producing CD4+ and CD8+ 
T cells in narcolepsy patients. Similarly, B cells of narcolepsy 
patients also expressed TNF at a higher frequency than HD. 
These findings are in line with TNF being previously im-
plicated in narcolepsy by genetic association (Hohjoh et al., 
1999) and by increased plasma levels in narcolepsy patients 
(Himmerich et al., 2006; Tanaka et al., 2014). Interestingly, by 
performing linear modeling, we found this narcolepsy-spe-
cific polarization of cytokine production to become more 
pronounced in patients with longer disease duration and 
higher age. This analysis could not be performed in patients 
with other hypersomnias, as this group was underpowered 
to specifically study the impact of age on the measured im-
mune parameters. However, the age-dependent progression 
of cytokine production in narcolepsy patients is striking and 
matches previous studies reporting increased levels of IL-4 
in the CSF of narcolepsy patients with long disease duration 
(Dauvilliers et al., 2014), but not patients with short disease 
duration (Kornum et al., 2015).
This might reflect the presence of an underlying in-
flammatory milieu in narcolepsy patients, which is absent 
in nondiseased controls. Several factors could contribute to 
such an environment, among them disturbance of sleeping 
patterns (Vgontzas et al., 1997; Ackermann et al., 2012; Aho 
et al., 2013; Lasselin et al., 2015), circadian rhythm (Schei-
ermann et al., 2013; Spitzer et al., 2015), treatment with 
psychostimulants (Filiano et al., 2016), and associated met-
abolic changes (Wolowczuk et al., 2008). To control for 
these potential effects, we included patients with sleep dis-
orders that exhibit similar manifestations and comorbidi-
ties and undergo overlapping treatment. Importantly, these 
hypersomnia patients were immunologically distinct from 
narcolepsy patients and did not present increased cytokine 
production found in narcolepsy patients. However, type 1 
narcolepsy patients tend to have more severe sleepiness and 
more disturbed sleep compared with patients with other 
hypersomnia. Therefore, we directly modeled the potential 
influence of sleepiness, disturbed night-time sleep, depres-
sive symptoms, BMI, and treatment status on all reported 
immune phenotypes. Besides IL-4 expression by CD8+ T 
cells, we did not find any correlation of these clinical pa-
rameters with the narcolepsy-associated immune pheno-
types. Apart from these patient characteristics, it is possible 
that independent from narcolepsy, the genetic background 
contributes to this immune polarization over time. How-
ever, to control for this effect, we matched the HD with 
Figure 4. Stability of the narcolepsy-related immune phenotypes 
across independent experiments and different draws. Log-trans-
formed frequencies of all previously defined immune phenotypes assessed 
by multiple measurements. (A) Different aliquots from the same draws 
were repeatedly measured in independent experiments (two independent 
repetitions; n = 10, left; n = 12, right). (B) Repeated measurements of nar-
colepsy samples from different blood draws (n = 12). Correlation coeffi-
cients were calculated using a linear regression model.
Figure 5. Immune phenotypes of narcolepsy patients 
stratified for Pandemrix vaccination. Benjamini-Hoch-
berg corrected log-transformed p-values derived from 
Mann-Whitney-Wilcoxon tests comparing Pandemrix-vac-
cinated (n = 11) with non-Pandemrix vaccinated narcolepsy 
patients (n = 12). Only narcolepsy patients matched for dis-
ease duration and age were included in this comparison. The 
horizontal line indicates p-values that are considered signif-
icant with a FDR < 10%.
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regard to the major susceptibility gene variant, presence of 
the HLA-DQB1*06:02 allele.
Contrasting with the increase of narcolepsy-associated 
cytokine patterns over time, elevated expression of CD69 
on T cells from narcolepsy patients was most pronounced in 
younger patients with short disease duration, and decreased 
over time. Together with the modulation of cytokine pro-
duction patterns, this suggests a progressive shift from early 
T cell activation to functional polarization. Longitudinal 
follow up of cohorts of patients with narcolepsy should 
help clarify this aspect.
Narcolepsy patients matched for age and short dis-
ease duration but grouped into Pandemrix-vaccinated and 
non–Pandemrix-vaccinated were found to be largely indis-
tinguishable by single-cell cytometry (Carr et al., 2016). In 
agreement with studies on genetic (Nguyen et al., 2016) and 
clinical (Pizza et al., 2014) features of post-Pandemrix versus 
sporadic narcolepsy, our results support a shared pathophys-
iology regardless of vaccine association. Whether exposure 
to similar environmental factors (for instance vaccination 
vs. natural infection) is the reason for the lack of detectable 
differences between Pandemrix-vaccinated and non–Pan-
demrix-vaccinated patients remains to be determined. Lastly, 
although mass cytometry enabled us to simultaneously an-
alyze 45 parameters and use this data to define numerous 
immunological phenotypes, this study mostly focused on 
lymphocyte activation, maturation, and cytokine production 
and did not include parameters necessary to study B cell mat-
uration/activation in depth.
This analysis included a monozygotic twin pair where 
both siblings received Pandemrix-vaccination but only one 
developed narcolepsy. Although the narcolepsy-associated 
augmented CD69 expression was confirmed in this single 
pair, the cellular composition was found to be similar in both 
twins. Study of such monozygotic twin pairs in a clinical 
context can be extremely valuable. However, given the rel-
ative rarity of narcolepsy, only a single twin pair could be 
included here, which limits the possibility to draw firm con-
clusions regarding the pathogenesis of narcolepsy in geneti-
cally identical individuals.
Given technical considerations and the limitation in 
sample availability of this rare disorder, this study addressed 
changes in the recirculating immune system but not the tis-
sue-infiltrating leukocyte compartment of the CNS directly. 
Figure 6. narcolepsy-associated immune phenotypes are influenced by age and disease duration. Immune phenotypes of all narcolepsy patients 
(n = 39) and HD (n = 25) were included in this analysis. (A) R2-values (top) and –log10 of Benjamini-Hochberg–adjusted p-values (bottom) of linear re-
gression models relating immunological phenotypes with age in narcolepsy patients and HD. The horizontal line indicates p-values that are considered 
significant with a FDR < 10%. (B) Changes of selected immune phenotypes for narcolepsy patients (red) and HD (blue) with age. The shaded area represents 
the 95% confidence interval of the linear model. (C) Proportion of R2 for narcolepsy patients (n = 39) explained by disease duration and age. (D) Benjami-
ni-Hochberg-adjusted p-values of linear models relating immunological phenotypes in narcolepsy patients with clinical parameters. 
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However, recent studies suggest a previously underappreci-
ated functional link between the CNS and peripheral im-
munity (Kim et al., 2015; Louveau et al., 2015), and we thus 
believe that these results will be highly beneficial to guide 
future studies in generating more precise hypotheses which 
can be verified, e.g., in the CSF of patients.
Because of the unknown nature of a potential autoanti-
gen in narcolepsy, we could not investigate the antigen-spec-
ificity of lymphocyte populations. This remains an aspect of 
great importance and it will be interesting to see whether 
the above-indicated expansion of certain T cell subsets would 
concur with a specific pattern of clonal expansion.
A surprisingly high frequency of T cells in patients with 
narcolepsy exhibited an inflammatory signature character-
ized by elevated expression of activation markers or cyto-
kine production. This frequency by far exceeds the expected 
frequency of (auto)antigen-specific T cells as detected by 
MHC/peptide tetramer staining in other contexts (Pepper 
et al., 2010; Yu et al., 2015). It is unlikely, due to lack of sen-
sitivity of current tools, to selectively analyze disease-caus-
ing autoreactive T cells, although innovative tools are now 
available to test this hypothesis provided autoantigens and 
HLA-binding peptide thereof, are identified (Huang et al., 
2016). More likely, disease progression impacts on general im-
mune cell activation and function. Precedent for broad T cell 
alterations in organ-specific autoimmune diseases has been 
reported, although the exact mechanisms involved still escape 
current understanding (McKinney et al., 2015).
Although sharing many clinical characteristics with 
type 1 narcolepsy, patients with other hypersomnias do not 
suffer from the lack of orexin-producing neurons and as-
sociated cataplexy episodes, both of which are used for the 
diagnosis of narcolepsy. For this study, we measured CSF 
orexin levels for the majority of narcolepsy patients (32 of 
39) and patients with other causes of hypersomnia (10 of 
11), whereas the remaining were classified based on clin-
ical parameters and the documented presence or absence 
of cataplexy according to International Classification of 
Sleep Disorders, third edition guidelines (American Acad-
emy of Sleep Disorders, 2014). The impact of chronic 
depletion of the orexin neuropeptide on immune cell ac-
tivation is unknown. It is tempting to speculate that orexin 
can affect immune cell biology and that its chronic defi-
ciency in patients with narcolepsy somehow promotes gen-
eral immune dysregulation.
Collectively, we believe that this high-dimensional, 
single-cell analysis approach represents a comprehensive 
account of the immunological signature found in narco-
lepsy patients. It revealed narcolepsy-associated immune 
activation and increased B cell–supporting cytokine pro-
duction, the magnitude of which is dependent on disease 
duration and age. These findings thus offer insight into 
the nature of the underlying history and current periph-
eral immune-milieu in this elusive disease. In addition, it 
provides a rationale for the further investigation of lym-
phocytes and associated effector mechanisms as therapeu-
tic targets in narcolepsy.
MAterIALS And MetHodS
Patient samples
Patients (Table 1 and Table S1) were characterized and their 
peripheral blood was collected at the National Reference 
Center for Orphan Sleep Disorders (Gui-de-Chauliac Hos-
pital, Montpellier, France). Cryopreservation of PBMCs 
from patients and from healthy volunteers was performed at 
Institut National de la Santé et de la Recherche Médicale 
U1043 (Toulouse, France) within 24 h of blood collection. 
Narcolepsy type 1 was diagnosed according to International 
Classification of Sleep Disorders, third edition based on the 
presence of excessive daytime sleepiness, clear-cut cataplexy, 
≥2 SOR EMPs, and mean sleep latency <8 min on the MSLT, 
or CSF orexin levels <110 pg/ml. A video documentation 
of clear-cut cataplexy was available to confirm the diagnosis 
in all patients without CSF orexin measurement. All patients 
were HLA-DQB1*06:02 positive. Samples defined as other 
sleep disorders showed normal CSF orexin concentrations, 
i.e., >200 pg/ml. All patients gave their written informed 
consent to take part in the research program, which was ap-
proved by the local ethics committee (Comité de Protection 
des Personnes–Ile de France 06). All mass cytometry experi-
ments and their initial analysis were performed blinded.
Genotyping
HLA typing of narcolepsy patients was performed by PCR 
sequence-specific oligonucleotides and four-digit allele as-
signments were performed by Luminex xMAP technology. 
To resolve ambiguous typing or degeneracy, direct PCR-se-
quencing with the following primers was used: forward, 5′-
CCC GCA GAG GAT TTC GTG TT-3′; reverse, 5′-AAC TCC 
GCC CGG GTC CC-3′. Internal control primers: forward, 
5′-TGC CAA GTG GAG CAC CCAA-3′; reverse, 5′-GCA 
TCTT-GCT CTG TGC AGAT-3′. Genomic DNA was am-
plified at 94°C for 15 min, followed by 35 cycles of 94°C for 
1 min, 63°C for 1 min, 72°C for 1 min, and 72°C for 10 min. 
The amplification produced a 217-bp band in the presence of 
DQB1*06:02, and a 700–730-bp internal control band.
ex vivo reactivation of PBMcs
Cryopreserved PBMCs were stored in liquid nitrogen until 
thawing in a 37°C water bath for 7 min. Cells were resus-
pended gently in 1 ml of prewarmed cell culture medium 
(CCM; RPMI-1640 [PAN biotech], 10% FCS [Biochrom]), 
1× l-glutamine, and 1× penicillin/streptomycin [both Life 
Technologies]) supplemented with 1:10,000 benzonase 
(Sigma-Aldrich), transferred into tubes containing 10 ml of 
CCM, and centrifuged (300 rcf, 7 min, 24°C). Washing with 
CCM was repeated once before counting and adjusting to 
106 cells/ml in CCM and resting overnight at 37°C. To deter-
mine cytokine production by mass cytometry, cells were stim-
ulated with 50 ng/ml phorbol 12-myristate 13-acetate (PMA; 
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Sigma-Aldrich) and 500 ng/ml ionomycin (Sigma-Aldrich) 
in the presence of 1x Brefeldin A (BD) for 4 h at 37°C.
Antibodies
Monoclonal anti–human antibodies (Table S2) were pur-
chased either preconjugated to heavy-metal isotopes from 
Fluidigm or from commercial suppliers in purified form and 
conjugated in house using the Maxpar X8 chelating polymer 
kit (Fluidigm) according to the manufacturer's instructions.
Live cell barcoding
To reduce inter-sample staining variability, minimize sam-
ple-handling time, and reduce antibody consumption, we 
made use of the live-cell barcoding approach (Mei et al., 
2015). Therefore, isothiocyanobenzyl-EDTA (p-SCN-EDTA; 
Dojindo) was loaded with five different palladium isotopes 
(104Pd, 105Pd, 106Pd, 108Pd, and 110Pd) and one indium isotope 
(115In; all from Trace Sciences International) as previously de-
scribed (Zunder et al., 2015) and subsequently used to label 
anti–human CD45 (BioLegend). In addition, preconjugated 
89Y-CD45 (Fluidigm) was used as a seventh barcoding reagent. 
To obtain robust barcoding results with even staining intensity 
on all samples, either a 6-choose-2 or a 7-choose-3 scheme 
was used, resulting in 15 or 35 different combinations of two 
heavy metal–labeled CD45 antibodies, respectively. PBMCs 
were labeled with metal-tagged CD45 antibodies after ex vivo 
reactivation at 37°C for 25 min in cell staining medium (CSM; 
RPMI-1640, 4% FCS) on a rotating shaker (500 rpm). Samples 
were washed twice in CSM and combined into a single reac-
tion vessel for further staining steps.
Surface staining
After live cell barcoding, the combined sample was centri-
fuged, supernatant was aspirated, and cells were resuspended 
in 300 µl of antibodies (Table S2) in CSM. Cells were stained 
for 20 min at 37°C on a rotating shaker (500 rpm) to opti-
mize CCR staining (Berhanu et al., 2003). Dead cells were 
excluded by adding 1 ml of 2.5 µM cisplatin (Sigma-Aldrich) 
in PBS at the end of the staining period and incubating for 
2 min on ice (Fienberg et al., 2012). Afterward, the sample 
was washed once in PBS supplemented with 0.5% BSA 
(PBS/BSA; Sigma-Aldrich).
Intracellular cytokine staining
Surface-stained cells were fixed by resuspending them in 1.6% 
paraformaldehyde (PFA; Electron Microscopy Sciences) for 
30 min at 4°C on a rotary shaker (500 rpm). Afterward, the 
sample was washed twice with permeabilization buffer (PBS, 
0.5% saponin, 2% BSA, and 0.01% sodium azide [all from 
Sigma-Aldrich]), the supernatant was aspirated and the sam-
ple was resuspended in 300 µl of antibody mixture (Table S2) 
in permeabilization buffer for 1 h at 4°C on a rotary shaker 
(500 rpm). The sample was washed with permeabilization 
buffer, supernatant was aspirated, and the cells were resus-
pended in 500 µl of iridium intercalator solution (Fluidigm) 
overnight. Next, the sample was washed twice with PBS/
BSA, once with ddH2O, resuspended at 0.5–106 cells/ml and 
filtered through a cell strainer cap (Falcon) before acquisition.
Acquisition on cytoF2 mass 
cytometer and data preprocessing
Samples were acquired on a CyTOF2 mass cytometer (DVS 
Sciences/Fluidigm). Quality control and tuning processes 
were performed on a daily basis before acquisition. Data from 
different days was normalized by adding five-element beads 
(Fluidigm) to the sample immediately before acquisition and 
using the Matlab-based normalization software as described 
previously (Finck et al., 2013). Only events with Event_
length between 10 and 100 were exported. Before down-
stream analysis, live cells were exported by manual gating 
on Event_length, DNA (191Ir and 193Ir), and live cells (195Pt) 
using FlowJo software (Tree Star). Next, cells were assigned to 
their initial samples using a dedicated debarcoding software 
(Zunder et al., 2015). Bead-normalized files were imported 
into the R environment and transformed using an inverse 
hyperbolic sine (arcsinh) function with a cofactor of 5 (Ben-
dall et al., 2011). To equalize the contribution of each marker 
in subsequent automated data analysis steps, we performed 
background subtraction and percentile normalization (Levine 
et al., 2015). Therefore, we normalized all data to the 99.5th 
percentile of the combined (barcoded) sample. This preserves 
inter-sample variability in maximum expression values, which 
might be biologically relevant. Markers expressed with a low 
frequency of PBMCs (mostly cytokines) were normalized to 
the 99.995th percentile.
Automated population identification in high-
dimensional data analysis
After preprocessing, all samples from all cohorts were down 
sampled to a maximum of 100’000 cells per sample, com-
bined into one file and subjected to the FlowSOM clustering 
algorithm to identify meaningful immunological populations. 
We choose FlowSOM over other clustering options for sev-
eral reasons: (i) in our hands it identified clusters which ef-
ficiently represented immune populations that we expected 
to be present based on prior biological knowledge, (ii) its 
availability within the R environment which enabled us to 
perform large parts of the analysis in a streamlined way, (iii) 
it was able to perform clusterings within a few minutes on 
a standard desktop computer enabling us to run it multiple 
times and thus compare the influence of different input pa-
rameters, especially the k-value used in the meta-clustering 
step. FlowSOM was run on the combined sample to facilitate 
the identification of small populations that could be over-
looked when clustering is performed on each single sample. 
After the initial clustering step, resulting nodes were subjected 
to meta-clustering. The respective k-value was chosen manu-
ally and in a way so that we were still able to identify all pop-
ulations that were expected to be present, based on general 
biological knowledge. Heat maps display median expression 
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levels for the indicated populations and were drawn using the 
ggplot2 R package. Dendrograms were calculated using hi-
erarchical clustering. Correlation coefficients were calculated 
using the stats package.
Statistical analysis
Population frequencies or medians in narcolepsy and HD 
samples were compared using a nonparametric Mann-Whit-
ney-Wilcoxon test. Samples with a low live cell count were 
excluded from the final analysis. In case we tested for the mod-
ulation of multiple markers or clusters at once, we controlled 
for multiple comparisons by using the Benjamini-Hochberg 
approach using R (Noble, 2009; McDonald, 2014). P-values 
were reported together with an estimate of the false discovery 
rate with which the p-values would be considered significant. 
Linear regression was performed with the R base function 
lm and the relative contributions were calculated with the 
relaimpo package (Grömping, 2006).
online supplemental material
Table S1 shows clinical and demographic characteristics of 
all individuals evaluated in this study. Table S2 shows the 
heavy metal-labeled antibody panel for mass cytometry. Table 
S3 shows frequencies of the reported immune phenotypes 
for all individuals evaluated in this study. Tables S1–S3 are 
available as Excel files.
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